학술논문
The liver fibroinflammatory marker cT1 is reduced with aldafermin therapy in a randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
16000641